The R27080 glycoprotein is abundantly secreted from human cytomegalovirus-infected fibroblasts.

A 45 kDa glycoprotein was purified from the culture media of human cytomegalovirus (HCMV)-infected fibroblasts. N-terminal sequencing revealed that the protein, R27080, is the translation product of the R27080 open reading frame of HCMV. R27080 is highly glycosylated and contains no cysteine or methionine residues. Proteolytic cleavage of R27080 by a furin-like enzyme was analysed in transfected COS-7 cells. R27080 is the first identified viral protein secreted from HCMV-infected cells.

Expression and purification of correctly processed, active human TACE catalytic domain in Saccharomyces cerevisiae.

Human tumor necrosis factor-alpha (TNF alpha) converting enzyme (TACE) releases soluble TNF alpha from cells. It is a member of the adamalysin family of metalloproteases. A truncated form of TACE cDNA was expressed in Saccharomyces cerevisiae and purified to homogeneity in order to study TACE structure and function. Recombinant TACE was expressed as a preproprotein including the pro- and catalytic (PROCAT) domains fused to the yeast alpha-factor leader. A C-terminal immunoreactive FLAG peptide was added for Western blot detection and anti-FLAG antibody column purification. We constructed two glycosylation mutant PROCAT TACE isoforms to facilitate purification. A PROCAT isoform, mutated to eliminate two N-linked glycosylation sites, was buffer exchanged and purified to homogeneity by ion exchange chromatography and an anti-FLAG antibody affinity step. N-terminal sequence analysis showed that the mutant preproprotein was processed in yeast at the furin protease cleavage site and yielded an active catalytic domain which has TNF alpha peptide-specific protease activity. Mass spectrometry of the purified catalytic domain showed that removal of both N-linked sites results in a homogeneous sized polypeptide lacking further posttranslational modifications.

Characterization of the microheterogeneities of PIXY321, a genetically engineered granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein expressed in yeast.

PIXY321, a human cytokine analog genetically engineered by the fusion of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3), was expressed in yeast under the control of the alcohol dehydrogenase 2 (ADH2) promoter and the alpha-mating factor expression system. To provide the material necessary for the evaluation of PIXY321 in clinical trials, the production was scaled up to the 1200-1 scale and the PIXY321 molecule isolated by four successive steps of ion-exchange chromatography. Multiple heterogeneities, due to the presence of different patterns of glycosylation as well as multiple amino acid sequences at both N and C termini, were characterized on the purified molecule using complementary analytical techniques including electrophoresis, liquid chromatography and electrospray mass spectrometry. Four different N-terminal sequences were identified but simplified to a reproducible ratio of two sequences, the mature form and a form starting at Ala3, by adjustment of the process conditions. Molecules lacking 1-6 residues at the C-terminus were identified and their relative frequencies quantified. Amino acid modifications, such as three oxidized Met residues at positions 79, 141 and 187 and one deamidated Asn residue at position 176, were detected at low level. Microheterogeneities in glycosylation were characterized on four different sites, one located in the GM-CSF portion and three in the IL-3 portion of the molecule. The sites were shown to be differentially occupied and to carry 0-10 mannose residues according to their location in the sequence. Precise measurement of the heterogeneities at the molecular level were used to tune the process conditions and ensure reproducibility of the clinical product between lots.

TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

TRAIL is a member of the tumor necrosis factor (TNF) family of cytokines and induces apoptosis in a wide variety of cells. Based on homology searching of a private database, a receptor for TRAIL (DR4 or TRAIL-R1) was recently identified. Here we report the identification of a distinct receptor for TRAIL, TRAIL-R2, by ligand-based affinity purification and subsequent molecular cloning. TRAIL-R2 was purified independently as the only receptor for TRAIL detectable on the surface of two different human cell lines that undergo apoptosis upon stimulation with TRAIL. TRAIL-R2 contains two extracellular cysteine-rich repeats, typical for TNF receptor (TNFR) family members, and a cytoplasmic death domain. TRAIL binds to recombinant cell-surface-expressed TRAIL-R2, and TRAIL-induced apoptosis is inhibited by a TRAIL-R2-Fc fusion protein. TRAIL-R2 mRNA is widely expressed and the gene encoding TRAIL-R2 is located on human chromosome 8p22-21. Like TRAIL-R1, TRAIL-R2 engages a caspase-dependent apoptotic pathway but, in contrast to TRAIL-R1, TRAIL-R2 mediates apoptosis via the intracellular adaptor molecule FADD/MORT1. The existence of two distinct receptors for the same ligand suggests an unexpected complexity to TRAIL biology, reminiscent of dual receptors for TNF, the canonical member of this family.

T1/ST2 signaling establishes it as a member of an expanding interleukin-1 receptor family.

Through data base searches, we have discovered new proteins that share homology with the signaling domain of the type I interleukin-1 receptor (IL-1RI): human "randomly sequenced cDNA 786" (rsc786), murine MyD88, and two partial Drosophila open reading frames, MstProx and STSDm2245. Comparisons between these new proteins and known IL-1RI homologous proteins such as Toll, 18-Wheeler, and T1/ST2 revealed six clusters of amino acid similarity. We tested the hypothesis that sequence similarity between the signaling domain of IL-1RI and the three mammalian family members might indicate functional similarity. Chimeric IL-1RI receptors expressing the putative signaling domains of T1/ST2, MyD88, and rsc786 were assayed by three separate IL-1 responsive assays, NF-kappaB, phosphorylation of an epidermal growth factor receptor peptide, and an interleukin 8 promoter-controlled reporter construct, for their ability to transduce an IL-1-stimulated signal. All three assays were positive in response to the T1/ST2 chimera, while the MyD88 and rsc786 chimeras failed to respond. These data indicate that the sequence homology between IL-1RI and T1/ST2 indicates a functional homology as well.

Ethanol inhibits some of the early effects of epidermal growth factor in vivo.

Charles River male Wistar rats (200-300 g) were meal fed for 9-10 days, injected with either saline, epidermal growth factor (EGF), ethanol, or ethanol combined with EGF and their livers were freeze clamped 5 min after intraperitoneal injection of EGF. Metabolites were measured and the redox state and phosphorylation potential were calculated. Epidermal growth factor alone elevated hepatic content of glucose 1-P, glucose 6-P, fructose 6-P, and 3-phosphoglycerate 1.2-1.3-fold when compared to saline treatment. Ethanol alone decreased hepatic content of 3-phosphoglycerate and phosphoenolpyruvate 3.2-3.7-fold below saline-treated levels. Ethanol, in combination with EGF, decreased hepatic values for 3-phosphoglycerate and phosphoenolpyruvate 2.0-2.3-fold from saline treatment but elevated the content of phosphoenolpyruvate 1.6-fold over ethanol treatment alone. Epidermal growth factor inhibited pyruvate kinase activity 1.3-fold when compared to saline controls but ethanol in the presence of EGF facilitated the recovery of activity of this enzyme.

Epidermal growth factor binding in the presence of ethanol.

Epidermal growth factor (EGF) is a mitogen which has been shown to stimulate maxillo-facial growth and DNA synthesis. Ethanol has been reported to inhibit cell regeneration in vivo and in vitro and to produce diminished maxillo-facial development in fetal alcohol syndrome. Recent findings from this laboratory have elucidated rapid metabolic changes in the hepatic content of some of the glycolytic intermediates resulting from injection of EGF, ethanol or EGF combined with ethanol in vivo. An immediate effect of EGF in vivo is to increase hepatic tissue content of 3-phosphoglycerate and phosphoenolpyruvate 1.2-1.3 fold when compared to saline treatment. Ethanol however causes a marked fall in the hepatic content of 3-phosphoglycerate and phosphoenolpyruvate 3.2-3.7 fold below saline treated levels. Ethanol in combination with EGF decreases hepatic values for 3-phosphoglycerate and phosphoenolpyruvate 2.0-2.3 fold from saline treated, but elevates the content of phosphoenolpyruvate 1.6 fold over ethanol treatment alone. Such metabolite changes occurring with ethanol treatment have been attributed alternately to redox shifts or to membrane perturbations. We wished to determine whether dimunition of 3-phosphoglycerate and or phosphoenolpyruvate below certain levels perhaps critically necessary for normal mitogenic action of EGF was due in this case to ethanol effects of binding of EGF to the cell membrane.

Alterations in brain lipid composition of mice made physically dependent to ethanol.

The ability of chronic ethanol treatment to alter CNS membrane lipids was tested. Adult C57/BL6 mice were given a liquid diet containing ethanol for eight days. This regimen produced strong physical dependence as judged by withdrawal seizures, tremors and concomitant hypothermia. Analyses were performed on cholesterol, total phospholipid content and total phospholipid acyl composition of myelin, crude (P2), light and heavy synaptosomes as well as synaptosomal plasma membranes. Chronic ethanol treatment had no effect on total phospholipid levels nor phospholipid acyl composition in any of the above subcellular fractions. In ethanol dependent mice, significant increases in cholesterol content and cholesterol/phospholipid ratios were observed in synaptosomal plasma membranes.

Effects of ethanol diets on cholesterol content and phospholipid acyl composition of rat hepatocytes.

Chronic treatment of adult male rats with ethanol liquid diets resulted in alterations in phospholipid and cholesterol contents as well as the acyl composition of phosphatidylethanolamine (PE), phosphatidylinositol (PI)-phosphatidylserine (PS) mixture, and phosphatidylcholine (PC) of isolated hepatocytes. The influence of ethanol on these lipids was largely dependent on the proportion of dietary fat. Phospholipid and total cholesterol contents were elevated 23 and 27%, respectively, by ethanol when offered in a low-fat diet (5% corn oil). Only the percentage of arachidonic acid from PI-PS was significantly reduced in the low-fat ethanol group. Exposure to a high-fat (34% corn oil) diet in the presence of ethanol for 4-5 weeks resulted in a significant decrease in arachidonate/linoleate ratios of hepatic PE, PS-PI and PC, while total phospholipid content remained constant. In the high-fat, ethanol-treated group, hepatic cholesterol content was increased 2-fold. These results suggest that the level of dietary fat plays an important role in determining the effects of chronic ethanol consumption on hepatic cholesterol content and phospholipid acyl composition.